RESUMEN
INTRODUCTION: Heart transplant is the ultimate treatment for patients with end-stage heart failure. AIM: To assess 50 heart transplant patients for underlying diseases, transplantation outcome and mortality rate during a 5-year follow-up program. MATERIAL AND METHODS: Fifty heart transplant patients who underwent heart transplantation from 2012 to 2017 were assessed for underlying diseases, organ rejection, duration of hospitalization, extubation time, cardiac output and survival. Biopsy samples were obtained after surgery for evaluation of rejection. RESULTS: Dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) were the most common underlying diseases with prevalence of 56% and 12%, respectively. Significant improvement in ejection fraction was observed following heart transplant. Minimum and maximum extubation and hospitalization times were 3-408 hours and 1-51 days, respectively. Organ rejection evaluation 10 days after heart transplantation revealed that 50% of patients did not show any rejection while 10% had severe rejection. At 30 days post-operatively the number of patients with grade III rejection decreased to 2% while 56% of patients had no sign of rejection. The 5-year survival rate was 66% while infection and arrhythmia were the most common causes of death. CONCLUSIONS: DCM and ICM are considered the most prevalent underlying diseases in heart transplant candidates. Ejection fraction reached normal ranges following transplant, which provides good quality of life. Low incidence of severe acute rejection demonstrates the effectiveness of our immunosuppressive therapy. In the cases of increased rejection, the patient's immunosuppressive regimen was re-assessed accordingly.
RESUMEN
BACKGROUND: trans-Resveratrol (t-Res) is a natural phenolic compound with various biological activities such as antioxidant, anticancer, cancer chemopreventive, cardioprotective, and neuroprotective. OBJECTIVES: There is no comprehensive study about the stability of t-Res in human plasma. With respect to extensive use of t-Res in clinical trials and pharmacokinetic studies, in this study, we aimed to measure the plasma stability of t-Res at different conditions of lighting, pH, and temperature, and in the presence of routine antioxidant agents (BHT and VIT C). MATERIALS AND METHODS: t-Res stability in human plasma was evaluated at different conditions of lighting, pH and temperature, and in the presence of routine antioxidant agents (BHT and VIT C), and quantitatively determined using HPLC-UV method at 306 nm. RESULTS: Our findings revealed that t-Res was quite stable in different temperatures ranging from -70 °C to 25 °C, and acidic pH conditions in plasma for a month, when protected from light, but it was unstable in alkali pH and in lighting conditions. CONCLUSIONS: In lighting conditions, most of t-Res was isomerized to the other isomer cis-resveratrol. t-Res is unstable in alkali pH and when exposed to light. t-Res was quite stable at other conditions, and several freeze-thaw cycles did not have any effect on its stability.